Skip to Main Content

WASHINGTON — Justin Gover joined GW Pharmaceuticals, a company laser-focused on creating cannabinoid-based medicines, back in 1999, a time when the acronym CBD meant virtually nothing to most Americans, and more than two-thirds of Americans opposed the legalization of marijuana.

Fast forward 20 years and GW is in the middle of a CBD boom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.